Targets › TRBC1
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2028.
Constant region of T cell receptor (TR) beta chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01850)
Open in Phaseline: the race on TRBC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | iDLI (innate donor lymphocyte infusion) TCRαβ/CD19 depleted donor lymphocyte infusion enriched for NK cells (>10e7 cells/kg) and T | TRBC1, TRBC2, CD19 | Phase 2 | AML/MDS | Jan 2028 |
| Peking University People's Hospital | Reduced ATG plus mini PTCy Combination of anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PT | TRAC, TRBC1, TRBC2 | Phase 2 | Myelodysplastic Syndrome | – |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Anti-TRBC1 CAR-NK cells Umbilical cord blood-derived NK cells expressing anti-TRBC1/2 CAR | TRBC1, TRBC2 | Phase 1 | Refractory/Recurrent Peripheral T-cell Lymphoma | Jan 2029 |
Refractory/Recurrent Peripheral T-cell Lymphoma (1) Myelodysplastic Syndrome (1) AML/MDS (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.